[go: up one dir, main page]

ECSP13012520A - Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación - Google Patents

Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación

Info

Publication number
ECSP13012520A
ECSP13012520A ECSP13012520A ECSP13012520A EC SP13012520 A ECSP13012520 A EC SP13012520A EC SP13012520 A ECSP13012520 A EC SP13012520A EC SP13012520 A ECSP13012520 A EC SP13012520A
Authority
EC
Ecuador
Prior art keywords
preparation
pan
formula
intermediaries
cdk inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Jorma Hassfeld
Joachim Krüger
Jörg Gries
Kai Lovis
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012520(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP13012520A publication Critical patent/ECSP13012520A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Nuevo proceso para la preparación de inhibidores de pan-CDK de la fórmula (I), e intermediarios que se utilizan en la preparación.
ECSP13012520 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación ECSP13012520A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010046720A DE102010046720A1 (de) 2010-09-23 2010-09-23 Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung

Publications (1)

Publication Number Publication Date
ECSP13012520A true ECSP13012520A (es) 2013-05-31

Family

ID=44677881

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012520 ECSP13012520A (es) 2010-09-23 2013-03-22 Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación

Country Status (32)

Country Link
US (1) US9359306B2 (es)
EP (1) EP2619186A1 (es)
JP (1) JP5969993B2 (es)
KR (1) KR20130109145A (es)
CN (1) CN103119026B (es)
AP (1) AP2013006816A0 (es)
AR (1) AR083171A1 (es)
AU (1) AU2011304365B2 (es)
BR (1) BR112013006720A2 (es)
CA (1) CA2811807A1 (es)
CL (1) CL2013000797A1 (es)
CO (1) CO6690779A2 (es)
CR (1) CR20130138A (es)
CU (2) CU20130044A7 (es)
DE (1) DE102010046720A1 (es)
DO (1) DOP2013000063A (es)
EC (1) ECSP13012520A (es)
GT (1) GT201300078A (es)
IL (1) IL225352A0 (es)
MX (1) MX2013003338A (es)
MY (1) MY160625A (es)
NZ (1) NZ608448A (es)
PE (1) PE20140182A1 (es)
PH (1) PH12013500554A1 (es)
RU (1) RU2585621C2 (es)
SA (1) SA111320775B1 (es)
SG (1) SG188967A1 (es)
TW (1) TWI530488B (es)
UA (1) UA110626C2 (es)
UY (1) UY33624A (es)
WO (1) WO2012038411A1 (es)
ZA (1) ZA201301799B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
MA51820A (fr) 2018-02-13 2021-05-19 Bayer Ag Utilisation de 5-fluoro-4-(4-fluoro-2-méthoxyphényl)-n-(4-[(s-méthylsulfonimidoyl)méthyl]pyridin-2-yl)pyridin-2-amine pour traiter un lymphome diffus à grandes cellules b
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118481A (en) * 1995-06-05 2000-08-31 Rhone Poulenc Agrochimie Sulfur compounds pesticidal compositions containing them and method of their application
EP1291336A3 (en) 2001-09-05 2003-10-08 Solvias AG Preparation of optically active alpha-hydroxyethers
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
BR112013006720A2 (pt) 2016-06-14
AP2013006816A0 (en) 2013-04-30
US20130245261A1 (en) 2013-09-19
AU2011304365A1 (en) 2013-04-11
TW201215596A (en) 2012-04-16
CN103119026B (zh) 2015-08-19
SG188967A1 (en) 2013-05-31
NZ608448A (en) 2014-10-31
JP5969993B2 (ja) 2016-08-17
KR20130109145A (ko) 2013-10-07
DE102010046720A1 (de) 2012-03-29
DOP2013000063A (es) 2013-04-30
ZA201301799B (en) 2014-05-28
TWI530488B (zh) 2016-04-21
CA2811807A1 (en) 2012-03-29
RU2585621C2 (ru) 2016-05-27
EP2619186A1 (de) 2013-07-31
AU2011304365B2 (en) 2015-02-05
CN103119026A (zh) 2013-05-22
IL225352A0 (en) 2013-06-27
UY33624A (es) 2012-04-30
CO6690779A2 (es) 2013-06-17
JP2013542189A (ja) 2013-11-21
WO2012038411A1 (de) 2012-03-29
GT201300078A (es) 2014-11-26
AR083171A1 (es) 2013-02-06
HK1185615A1 (en) 2014-02-21
MY160625A (en) 2017-03-15
US9359306B2 (en) 2016-06-07
MX2013003338A (es) 2013-06-24
UA110626C2 (uk) 2016-01-25
CU20150165A7 (es) 2016-05-30
CL2013000797A1 (es) 2013-09-13
CU20130044A7 (es) 2013-07-31
RU2013118432A (ru) 2014-10-27
CR20130138A (es) 2013-05-15
PE20140182A1 (es) 2014-02-14
SA111320775B1 (ar) 2015-02-03
PH12013500554A1 (en) 2013-05-06

Similar Documents

Publication Publication Date Title
DOP2013000063A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
SV2010003718A (es) Inhibidores de bace
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
TN2011000673A1 (en) Bace inhibitors
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UA114901C2 (uk) Інгібітори асс та їх застосування
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BR112013004490A2 (pt) aparelho para medir propriedade termodinâmicas de fluidos de reservatório, e método para medir propriedades termodinâmicas de fluidos de reservatório
UY33958A (es) Inhibidores de la glucosilceramida sintasa
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
CL2012003385A1 (es) Tratamiento para la incontinencia.
ECSP088961A (es) Nuevos herbicidas
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
UY33930A (es) Inhibidores novedosos de quinasas
MX2014007840A (es) Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
DOP2014000098A (es) 2-tiopirimidinonas
CL2012002082A1 (es) Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
UY34016A (es) Nuevo uso de aclidinio
UY34277A (es) Metodo para la eliminación del naftaleno
CU24289B1 (es) Nuevo procedimiento para la síntesis de la agomelatina